Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221622 · ClinicalTrials.gov registry record · Phase 1
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
A Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02221622 is a Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by University of Southern California. The registered enrollment target is 24 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02221622, a Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants. The primary goal is to determine the maximally tolerated dose.
Conditions Studied
Interventions
- DRUG Allopregnanolone injection (intravenous solution)
- DRUG Placebo injection (intravenous solution)
Study Locations (1)
California
- University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02221622
The ClinicalTrials.gov registry entry for NCT02221622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Allopregnanolone injection (intravenous solution) is the first listed.
NCT02221622 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02221622 about?
NCT02221622 is a clinical study titled "Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD". The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants. The primary goal is to determine the maximally tolerated dose.
What is the current status of trial NCT02221622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-08. Estimated completion is 2018-02.
What conditions does trial NCT02221622 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment.
What interventions are being tested in trial NCT02221622?
The interventions under investigation include: Allopregnanolone injection (intravenous solution) (DRUG), Placebo injection (intravenous solution) (DRUG).
Who is sponsoring clinical trial NCT02221622?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02221622 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.